Bremelanotide vs Cetrorelix
Head-to-head comparison of Bremelanotide (Bremelanotide (PT-141), cyclic melanocortin receptor agonist) and Cetrorelix (Cetrorelix acetate) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Bremelanotide | Cetrorelix |
|---|---|---|
| Category | Sexual Health | Sexual Health |
| Full Name | Bremelanotide (PT-141), cyclic melanocortin receptor agonist | Cetrorelix acetate |
| Molecular Weight | 1025.2 Da | 1431.06 Da |
| Half-Life | about 2.7 h | ~30 hours |
| Amino Acids | 7 | 10 |
| Typical Dose | 1.75 mg | 0.25 mg SC daily |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 200 | 300 |
| Research Status | Clinical | Clinical |
Bremelanotide Benefits
- ✓increases sexual desire
- ✓supports arousal
- ✓may improve erectile response
- ✓on-demand use
Cetrorelix Benefits
- ✓prevents premature ovulation
- ✓supports IVF cycle control
- ✓blocks LH surge
- ✓short-acting pituitary suppression
Bremelanotide Dosing
1.75 mg subcutaneous PRN|administer about 45 minutes before activity|max 1 dose per 24 hours
Cetrorelix Dosing
0.25 mg SC daily|start on stimulation day 5-6|protocol-dependent antagonist cycle
Bremelanotide Side Effects
- ⚠nausea
- ⚠flushing
- ⚠headache
- ⚠transient blood pressure increase
Cetrorelix Side Effects
- ⚠injection-site reactions
- ⚠headache
- ⚠nausea
Research Overview
Bremelanotide
Human studies and approval data support meaningful effects on sexual desire in women, with a central mechanism involving melanocortin signaling. It is one of the most clinically relevant peptides in this category and is commonly used as the reference compound for PT-141-type research.
Cetrorelix
Cetrorelix is a cornerstone GnRH antagonist in assisted reproduction, with a fast onset and reversible suppression of LH. Trials show it improves cycle management by reducing premature ovulation during stimulation.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.